Boston Scientific (BSX) is a publicly traded Healthcare sector company. As of May 20, 2026, BSX trades at $56.63 with a market cap of $83.12B and a P/E ratio of 23.46. BSX moved -0.42% today. Year to date, BSX is -40.02%; over the trailing twelve months it is -46.74%. Its 52-week range spans $52.52 to $109.50. Analyst consensus is strong buy with an average price target of $89.12. Rallies surfaces BSX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Boston Scientific Coronary IVL Catheter Hits 93.3% Safety, 93.7% Effectiveness: Boston Scientific’s SEISMIQ 4CE Coronary IVL catheter achieved 93.3% freedom from major adverse cardiac events at 30 days versus an 86.2% goal in the 420-patient FRACTURE trial. Procedural success reached 93.7% for stent delivery with under 50% residual stenosis, surpassing the 85.8% target.
| Metric | Value |
|---|---|
| Price | $56.63 |
| Market Cap | $83.12B |
| P/E Ratio | 23.46 |
| EPS | $2.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $109.50 |
| 52-Week Low | $52.52 |
| Volume | 12.02M |
| Avg Volume | 0 |
| Revenue (TTM) | $20.61B |
| Net Income | $3.56B |
| Gross Margin | 69.17% |
27 analysts cover BSX: 0 strong buy, 26 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $89.12.